Soligenix Inc (SNGX) Stock Price, Quote & News

Company Profile

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 538 8200

Fax: 609 452 6467

Website: www.soligenix.com

Address:

29 Emmons Drive, Suite B-10, Princeton, United States

suchislife Dec. 6 at 6:29 PM

$SNGX what’s the short term target price? Thanks

0 · Reply

Nick_clap Dec. 6 at 12:58 AM

$SNGX sunny future

0 · Reply

NetworkNewsWire Dec. 5 at 3:33 PM

BioMedNewsBreaks — $SNGX Featured in BioMedWire Editorial on Rare Disease Therapies https://ibn.fm/lPJrx

0 · Reply

JohnTrack Dec. 5 at 1:49 PM

$SNGX headline crossed, check link... https://www.rapidticker.com/news/sngx-soligenix-inc-nasdaq-sngx-advancing-ed64a8

0 · Reply

Mapagotrades Dec. 5 at 1:31 PM

$SNGX $SGNX Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad

0 · Reply

SPYmyQQQ Dec. 4 at 9:21 PM

🎯 Target Hit 🏁 📨 From Nov 7, 2025 💊 $SNGX 💵 Entry: $1.3800 ✅ Ext: $1.6501 💰 P/L: +19.57% 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

jtabrizi Dec. 4 at 9:00 PM

$SNGX passengers get ready for lift off. Looking for openings above and beyond

0 · Reply

NetworkNewsWire Dec. 4 at 2:18 PM

Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations $SNGX $AMGN $FOLD $CTOR $TNXP https://ibn.fm/GbzxS

0 · Reply

NetworkNewsWire Dec. 3 at 5:47 PM

InvestorNewsBreaks – $SNGX Featured in BioMedWire Editorial Highlighting HyBryte(TM) and Rare Disease Policy https://ibn.fm/Ans1a

0 · Reply

Stock_Catcher Dec. 3 at 1:31 PM

$SNGX Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space

0 · Reply

Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space

Nov 19, 2025, 7:30 AM EST - 18 days ago

Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Nov 7, 2025, 7:30 AM EST - 4 weeks ago

Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results

Oct 14, 2025, 7:30 AM EDT - 7 weeks ago

Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma

Oct 7, 2025, 7:30 AM EDT - 2 months ago

Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Sep 30, 2025, 7:30 AM EDT - 2 months ago

Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Sep 29, 2025, 4:05 PM EDT - 2 months ago

Soligenix Announces Closing of $7.5 Million Public Offering

Sep 26, 2025, 6:33 AM EDT - 2 months ago

Soligenix Announces Pricing of $7.5 Million Public Offering

Sep 23, 2025, 7:30 AM EDT - 2 months ago

Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor

Sep 4, 2025, 7:30 AM EDT - 3 months ago

Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses

Sep 2, 2025, 7:30 AM EDT - 3 months ago

Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 18, 2025, 1:03 PM EDT - 3 months ago

Why Is Soligenix Stock Soaring On Monday?

Aug 18, 2025, 7:30 AM EDT - 3 months ago

FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results

Aug 14, 2025, 7:30 AM EDT - 4 months ago

Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results

Aug 8, 2025, 8:30 AM EDT - 4 months ago

NetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin Cancer

Jul 31, 2025, 7:30 AM EDT - 4 months ago

Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease

Jul 8, 2025, 7:30 AM EDT - 5 months ago

Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones

Jul 1, 2025, 7:30 AM EDT - 5 months ago

Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions

Jun 6, 2025, 9:37 AM EDT - 6 months ago

Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials

May 9, 2025, 7:30 AM EDT - 7 months ago

Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results

Apr 14, 2025, 7:30 AM EDT - 8 months ago

Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks

Mar 25, 2025, 8:30 AM EDT - 9 months ago

IBN Initiates Coverage of Soligenix Inc.

Mar 25, 2025, 7:30 AM EDT - 9 months ago

Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants

Mar 21, 2025, 7:30 AM EDT - 9 months ago

Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results

Mar 6, 2025, 7:30 AM EST - 9 months ago

HyBryte™ Treatment Studies Presented at Two Medical Conferences in March

Feb 4, 2025, 7:30 AM EST - 10 months ago

Soligenix to Present at BIO CEO & Investor Conference

Jan 16, 2025, 7:30 AM EST - 11 months ago

Soligenix to Present at Upcoming Investor Conferences

Jan 14, 2025, 7:30 AM EST - 11 months ago

HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

Dec 16, 2024, 7:30 AM EST - 1 year ago

Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Dec 2, 2024, 7:30 AM EST - 1 year ago

HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment

Nov 19, 2024, 7:30 AM EST - 1 year ago

Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Nov 15, 2024, 7:30 AM EST - 1 year ago

Soligenix to Present at November 21st Virtual Investor Summit Microcap Event

Nov 14, 2024, 7:15 AM EST - 1 year ago

Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease

Nov 8, 2024, 7:30 AM EST - 1 year ago

Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results

Oct 22, 2024, 7:30 AM EDT - 1 year ago

Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin

Oct 16, 2024, 7:30 AM EDT - 1 year ago

Soligenix Invited to Present at Upcoming Investor Conferences

Oct 7, 2024, 7:30 AM EDT - 1 year ago

HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference

Oct 3, 2024, 7:30 AM EDT - 1 year ago

Soligenix Announces Partnership with Sterling Pharma Solutions

Sep 20, 2024, 9:00 AM EDT - 1 year ago

Nova Minerals and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Sep 16, 2024, 7:30 AM EDT - 1 year ago

Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024

Sep 3, 2024, 7:30 AM EDT - 1 year ago

Soligenix Receives European Patent for Improved Production of Synthetic Hypericin

Aug 16, 2024, 9:00 AM EDT - 1 year ago

Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

AREC

Aug 9, 2024, 7:30 AM EDT - 1 year ago

Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results

Jul 15, 2024, 10:16 AM EDT - 1 year ago

PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results

Jul 9, 2024, 12:46 PM EDT - 1 year ago

Soligenix stock rallies 400% on positive HyBryte trial results

Jul 9, 2024, 12:11 PM EDT - 1 year ago

Crude Oil Down 1%; Soligenix Shares Surge

Jul 9, 2024, 11:38 AM EDT - 1 year ago

Nano-Cap Soligenix Stock Surges Over 200% On Tuesday, Here's Why

Jul 9, 2024, 7:30 AM EDT - 1 year ago

Expanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

Jun 25, 2024, 7:30 AM EDT - 1 year ago

Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma

Jun 14, 2024, 7:30 AM EDT - 1 year ago

A Comparison of Vaccine Technologies to be Presented at the ASM Microbe Conference

suchislife Dec. 6 at 6:29 PM

$SNGX what’s the short term target price? Thanks

0 · Reply

Nick_clap Dec. 6 at 12:58 AM

$SNGX sunny future

0 · Reply

NetworkNewsWire Dec. 5 at 3:33 PM

BioMedNewsBreaks — $SNGX Featured in BioMedWire Editorial on Rare Disease Therapies https://ibn.fm/lPJrx

0 · Reply

JohnTrack Dec. 5 at 1:49 PM

$SNGX headline crossed, check link... https://www.rapidticker.com/news/sngx-soligenix-inc-nasdaq-sngx-advancing-ed64a8

0 · Reply

Mapagotrades Dec. 5 at 1:31 PM

$SNGX $SGNX Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad

0 · Reply

SPYmyQQQ Dec. 4 at 9:21 PM

🎯 Target Hit 🏁 📨 From Nov 7, 2025 💊 $SNGX 💵 Entry: $1.3800 ✅ Ext: $1.6501 💰 P/L: +19.57% 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

jtabrizi Dec. 4 at 9:00 PM

$SNGX passengers get ready for lift off. Looking for openings above and beyond

0 · Reply

NetworkNewsWire Dec. 4 at 2:18 PM

Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations $SNGX $AMGN $FOLD $CTOR $TNXP https://ibn.fm/GbzxS

0 · Reply

NetworkNewsWire Dec. 3 at 5:47 PM

InvestorNewsBreaks – $SNGX Featured in BioMedWire Editorial Highlighting HyBryte(TM) and Rare Disease Policy https://ibn.fm/Ans1a

0 · Reply

Stock_Catcher Dec. 3 at 1:31 PM

$SNGX Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space

0 · Reply

NetworkNewsWire Dec. 2 at 2:27 PM

Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now $SNGX $PFE $MRK $BMY $INSM https://ibn.fm/gYs86

0 · Reply

NetworkNewsWire Dec. 1 at 7:18 PM

$SNGX Reaches Key Enrollment Milestone in Phase 3 Trial with Encouraging Blinded Response Rate https://ibn.fm/mSXRW

0 · Reply

Salvo1968 Nov. 30 at 6:48 PM

$SNGX You might want to take a closer look at Soligenix. Their HyBryte program has some interesting potential, and it could be worth doing your own research on it.

0 · Reply

RandomInvestor777 Nov. 28 at 11:38 PM

$SNGX Great pipeline, I think this will eithet get a partner or a M&A in 2026. PT 8$+

0 · Reply

NetworkNewsWire Nov. 28 at 7:47 PM

MissionIRNewsBreaks – $SNGX Advancing Heat-Stable Vaccine Platform with New Peer-Reviewed Data https://ibn.fm/OFVmk

0 · Reply

Nick_clap Nov. 27 at 5:08 PM

$SNGX little bit of an increase Nice to see. Hope for a big rally in the next few months

0 · Reply

GSlimzy Nov. 26 at 6:59 PM

$SNGX This thing is about to LIFT https://www.bing.com/ck/a?!&&p=aabb37d58a0401024491f86747ad93c27cea6498aa10f22cb94946cfb42791a6JmltdHM9MTc2NDExNTIwMA&ptn=3&ver=2&hsh=4&fclid=23b82dd0-d5cf-6817-0c42-3b5ed4a86926&psq=sngx+news&u=a1aHR0cHM6Ly9tZW5hZm4uY29tLzExMTAzOTgyMDAvU29saWdlbml4LUluYy1OQVNEQVEtU05HWC1FbGV2YXRlcy1BZHZpc29yeS1OZXR3b3JrLUFzLVJhcmUtRGlzZWFzZS1TdHJhdGVneS1BZHZhbmNlcw

0 · Reply

kellymone2 Nov. 25 at 11:12 AM

$SNGX watching 👁 What do you expect here in the next few months?

0 · Reply

NetworkNewsWire Nov. 24 at 8:54 PM

$SNGX Strengthens CTCL Program as DMC Flags No Safety Issues https://ibn.fm/nHqvM

0 · Reply

ZacksSCR Nov. 20 at 6:08 PM

$SNGX: Phase 3 FLASH2 Trial Enrolls 50th Patient; Interim Analysis in 2Q26 https://buff.ly/XGoMNe3

0 · Reply

billsmall Nov. 19 at 8:50 PM

$SNGX Bios getting bought right and left for nice premiums and this one just festers. Up until open then down all day everyday, except for the pump and dumps. When we talk about todays markets and companies just using them for capital with no regard for retail working class this is exactly what we're talking about.

0 · Reply

NetworkNewsWire Nov. 19 at 5:20 PM

BioMedNewsBreaks — $SNGX Completes Enrollment for Interim Analysis in Phase 3 FLASH2 Study of HyBryte https://ibn.fm/rlotQ

0 · Reply

Market Cap	16.24M
Revenue (ttm)	120,000.00
Net Income (ttm)	-8.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-6,891.67%
Debt to Equity Ratio	0.00

Volume	790,500
Avg Vol	1,167,178
Day's Range	N/A - N/A
Shares Out	10.09M
Stochastic %K	81%
Beta	1.83
Analysts	Strong Buy
Price Target	$17.50